Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,123.66
(
0.84%
)
US TECH 100
26,106.80
(
1.29%
)
Dow Jones
49,527.23
(
0.77%
)
Brent Oil
97.01
(
2.11%
)
Bitcoin
79,041.52
(
3.56%
)
News Focus
News Focus
Post# of 257437
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 188159

Friday, 04/17/2015 12:21:45 PM

Friday, April 17, 2015 12:21:45 PM

Post# of 257437
ABBV starts phase-1 trial of Imbruvica+ABT-199 in second-line MCL:

https://clinicaltrials.gov/ct2/show/NCT02419560

This is the kind of combination regimen that was an impetus for ABBV to pay so much for PCYC.

H/t @lomu_j.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today